A final rule released this week by the FDA outlines current good manufacturing practice standards for products that combine drugs, medical devices and biologics. The rule aims to clarify the CGMP criteria for new and existing combination products that are sold together or are "single-entity" combinations.
Final FDA rule on device, drug and biologic combos is available
SmartBrief Job Listings for Health Care
|Senior Director, Biostatistics||
|Associate - Food and Drug||
Keller and Heckman LLP
|Senior Paralegal - Research & Development, and Medical||